vs

Side-by-side financial comparison of Smith Douglas Homes Corp. (SDHC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Smith Douglas Homes Corp. is the larger business by last-quarter revenue ($260.4M vs $151.7M, roughly 1.7× Tarsus Pharmaceuticals, Inc.). Smith Douglas Homes Corp. runs the higher net margin — 1.4% vs -5.5%, a 6.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -9.4%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $8.7M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 17.3%).

Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SDHC vs TARS — Head-to-Head

Bigger by revenue
SDHC
SDHC
1.7× larger
SDHC
$260.4M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+137.8% gap
TARS
128.4%
-9.4%
SDHC
Higher net margin
SDHC
SDHC
6.9% more per $
SDHC
1.4%
-5.5%
TARS
More free cash flow
TARS
TARS
$4.2M more FCF
TARS
$13.0M
$8.7M
SDHC
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
17.3%
SDHC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SDHC
SDHC
TARS
TARS
Revenue
$260.4M
$151.7M
Net Profit
$3.5M
$-8.4M
Gross Margin
19.9%
Operating Margin
6.5%
-5.3%
Net Margin
1.4%
-5.5%
Revenue YoY
-9.4%
128.4%
Net Profit YoY
-14.3%
63.8%
EPS (diluted)
$0.39
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SDHC
SDHC
TARS
TARS
Q4 25
$260.4M
$151.7M
Q3 25
$262.0M
$118.7M
Q2 25
$223.9M
$102.7M
Q1 25
$224.7M
$78.3M
Q4 24
$287.5M
$66.4M
Q3 24
$277.8M
$48.1M
Q2 24
$220.9M
$40.8M
Q1 24
$189.2M
$27.6M
Net Profit
SDHC
SDHC
TARS
TARS
Q4 25
$3.5M
$-8.4M
Q3 25
$2.1M
$-12.6M
Q2 25
$2.4M
$-20.3M
Q1 25
$2.7M
$-25.1M
Q4 24
$4.1M
$-23.1M
Q3 24
$5.3M
$-23.4M
Q2 24
$3.6M
$-33.3M
Q1 24
$3.0M
$-35.7M
Gross Margin
SDHC
SDHC
TARS
TARS
Q4 25
19.9%
Q3 25
21.0%
Q2 25
23.2%
Q1 25
23.8%
Q4 24
25.5%
Q3 24
26.5%
Q2 24
26.7%
Q1 24
26.1%
Operating Margin
SDHC
SDHC
TARS
TARS
Q4 25
6.5%
-5.3%
Q3 25
6.6%
-12.2%
Q2 25
7.7%
-21.6%
Q1 25
8.7%
-33.5%
Q4 24
10.4%
-36.8%
Q3 24
14.2%
-52.3%
Q2 24
11.7%
-81.6%
Q1 24
11.3%
-136.5%
Net Margin
SDHC
SDHC
TARS
TARS
Q4 25
1.4%
-5.5%
Q3 25
0.8%
-10.6%
Q2 25
1.1%
-19.8%
Q1 25
1.2%
-32.1%
Q4 24
1.4%
-34.8%
Q3 24
1.9%
-48.7%
Q2 24
1.7%
-81.6%
Q1 24
1.6%
-129.4%
EPS (diluted)
SDHC
SDHC
TARS
TARS
Q4 25
$0.39
$-0.17
Q3 25
$0.24
$-0.30
Q2 25
$0.26
$-0.48
Q1 25
$0.30
$-0.64
Q4 24
$0.50
$-0.57
Q3 24
$0.58
$-0.61
Q2 24
$0.40
$-0.88
Q1 24
$0.33
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SDHC
SDHC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$12.7M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$86.7M
$343.4M
Total Assets
$557.6M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SDHC
SDHC
TARS
TARS
Q4 25
$12.7M
$417.3M
Q3 25
$14.8M
$401.8M
Q2 25
$16.8M
$381.1M
Q1 25
$12.7M
$407.9M
Q4 24
$22.4M
$291.4M
Q3 24
$23.7M
$317.0M
Q2 24
$17.3M
$323.6M
Q1 24
$32.8M
$298.5M
Total Debt
SDHC
SDHC
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
SDHC
SDHC
TARS
TARS
Q4 25
$86.7M
$343.4M
Q3 25
$82.2M
$335.1M
Q2 25
$80.0M
$332.6M
Q1 25
$76.9M
$342.5M
Q4 24
$73.6M
$224.5M
Q3 24
$68.4M
$237.5M
Q2 24
$62.1M
$252.2M
Q1 24
$59.7M
$275.2M
Total Assets
SDHC
SDHC
TARS
TARS
Q4 25
$557.6M
$562.2M
Q3 25
$571.6M
$534.6M
Q2 25
$570.2M
$495.0M
Q1 25
$513.9M
$500.8M
Q4 24
$475.9M
$377.0M
Q3 24
$460.1M
$376.3M
Q2 24
$429.3M
$376.8M
Q1 24
$401.3M
$349.3M
Debt / Equity
SDHC
SDHC
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SDHC
SDHC
TARS
TARS
Operating Cash FlowLast quarter
$9.8M
$19.3M
Free Cash FlowOCF − Capex
$8.7M
$13.0M
FCF MarginFCF / Revenue
3.4%
8.6%
Capex IntensityCapex / Revenue
0.4%
4.2%
Cash ConversionOCF / Net Profit
2.77×
TTM Free Cash FlowTrailing 4 quarters
$-36.9M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SDHC
SDHC
TARS
TARS
Q4 25
$9.8M
$19.3M
Q3 25
$22.8M
$18.3M
Q2 25
$-28.9M
$-29.4M
Q1 25
$-34.9M
$-20.7M
Q4 24
$5.5M
$-22.2M
Q3 24
$22.9M
$-8.7M
Q2 24
$39.0K
$-14.4M
Q1 24
$-9.3M
$-37.8M
Free Cash Flow
SDHC
SDHC
TARS
TARS
Q4 25
$8.7M
$13.0M
Q3 25
$21.4M
$16.3M
Q2 25
$-31.1M
$-30.4M
Q1 25
$-35.9M
$-21.2M
Q4 24
$4.8M
$-22.3M
Q3 24
$22.3M
$-8.9M
Q2 24
$-2.1M
$-15.4M
Q1 24
$-9.7M
$-38.0M
FCF Margin
SDHC
SDHC
TARS
TARS
Q4 25
3.4%
8.6%
Q3 25
8.2%
13.8%
Q2 25
-13.9%
-29.6%
Q1 25
-16.0%
-27.1%
Q4 24
1.7%
-33.5%
Q3 24
8.0%
-18.6%
Q2 24
-1.0%
-37.8%
Q1 24
-5.1%
-137.5%
Capex Intensity
SDHC
SDHC
TARS
TARS
Q4 25
0.4%
4.2%
Q3 25
0.5%
1.6%
Q2 25
0.9%
1.0%
Q1 25
0.5%
0.8%
Q4 24
0.2%
0.1%
Q3 24
0.2%
0.6%
Q2 24
1.0%
2.5%
Q1 24
0.2%
0.6%
Cash Conversion
SDHC
SDHC
TARS
TARS
Q4 25
2.77×
Q3 25
10.70×
Q2 25
-12.24×
Q1 25
-13.01×
Q4 24
1.33×
Q3 24
4.28×
Q2 24
0.01×
Q1 24
-3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SDHC
SDHC

Southeast$164.7M63%
Central$95.8M37%

TARS
TARS

Segment breakdown not available.

Related Comparisons